Q-Line Biotech Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/as-cab46b39957c54db986902ce.pdf

Key Takeaways


The H2 Bet: Why a ~5% H1 Must Become 25–30% Full-Year

Meenal Gupta: "Looking at also that our H2 is always better, so I think we do see 25 to 30% growth for the year, for the year, YOY."

Unit 4: The Production Ramp That Carries the Model

Ajay Kumar Mahanty: "More than 150 to 160, 150 crore rupees business at least we'll generate from C42."

Reagents: The Profit Engine and Strategic Center

Ajay Kumar Mahanty: "Our area of interest, that is not the instrument sale. Our area of interest basically is the reagent cell."

The Government-to-Private Pivot

Meenal Gupta: "So slowly, I think by the time- so we are almost at a 50-50% ratio right now, but I think when we reach March '27, it will be a 40-60%... And as we go into March '28, we are looking at further decreasing the government part of our business. It will be less than 30 to 40%, and these are the initiatives that, you know, consciously the management is making these steps to slightly move away from the government business so that the overall cash flow of the company can be improved."

New Product Pipeline and CDMO


Margins, Profitability, and the Hidalgo Consolidation


Guidance & Commitments

CommitmentSpecificsTimeline
Full-year FY27 revenue₹400 crore (25–30% YoY growth)FY27
FY28 revenue growthMaintain 25–30% growthFY28
Unit 4 (C42) revenueAt least ₹150–160 croreFY27
Unit 4 capacity utilization25–30%By 27 March FY27
Unit 4 monthly kit production35,000–40,000 kits/monthFrom this month (Q3 FY27)
Unit 4 revenue (FY28)>₹120 crore minimum; ₹250–300 crore if Class C & D licenses receivedFY28
Government-to-private mix40:60By March '27
Government-to-private mix<30–40% governmentBy March '28
Government-to-private mix~30:70FY29 perspective
FY27 EBITDA margin~28% (same as FY26)FY27
Hidalgo Medical revenue~₹130 croreFY27
Working capital improvement~30 days improvementBy FY27 end
Working capital normalization60–90 days (2–3 months)During FY28
Chemiluminescence launchCommercial launchLast quarter FY27
Reagent revenue share65–70% of total revenueLong-term (~5 years)
Interest cost saving₹4–5 croreH2 FY27

Key Metrics

MetricH1 FY27
Revenue from operations₹152 crore, +5.83% YoY
EBITDA₹39.57 crore, +10.02% YoY
EBITDA margin26.0%, improved 99 bps YoY from 25.1%
Gross margin62.2%, up from 57.7% in H1 FY26
Profit after tax₹19.60 crore, down from ₹21.32 crore in H1 FY26
Depreciation₹7.89 crore, up from ₹4.09 crore in H1 FY26; Unit 4 capitalization impact
Reagent business growth19.23% YoY
Trade market business growth~20.13% YoY
Instrument revenue change-29% YoY; government order execution delayed
Reagent share of total sales71%, up from 63% in H1 FY26
Product licenses at Unit 436, up from 9 as of 30 September
CDMO import order value€2.3 million, combined for Selectra Pro M and Microlab 300
Hidalgo Medical FY26 revenue~₹108 crore, up from ₹50.91 crore in 2024
Hidalgo Medical acquisition value~₹26.93 crore for 70% stake
Government share of total sales~60%; receivable cycle 4–5 months
Installed instrument base~16,000 instruments; hematology ~8,000–9,000, fully auto ~3,000